Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnosis, averaging 4 to 6 years, which exacerbates disease progression and leads to irreversible comorbidities such as cardiovascular disease, diabetes mellitus, and sleep apnea. Join our live symposium for a deep dive into the diagnostic guidelines and the latest clinical insights and treatment strategies to enhance patient care. Don’t miss this opportunity to gain practical, expert-driven guidance on optimizing acromegaly management.
Acromegaly Care: Individualized Diagnosis and Management Strategies
While attending ENDO 2025, discover the current recommendations and scientific data on the diagnosis and therapeutic management of acromegaly.
Live
Meeting
Information
July 13, 2025
07:00 PM - 09:00 PM PT
San Francisco Marriott Marquis
780 Mission St., Yerba Buena Ballroom Salons 10-14, San Francisco, California, United States
Share
Share
Share
Share this program on:
Details
Presenters
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Maria Fleseriu, MD
Professor of Medicine (Endocrinology, Diabetes and Clinical Nutrition) and Neurological Surgery
Director Pituitary Center
Oregon Health & Sciences University
Portland, OR
Dr. Fleseriu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Amolyt, Camurus, Crinetics Pharmaceuticals, Debiopharm, Recordati
Research: Crinetics Pharmaceuticals
Faculty:
Shlomo Melmed, MBChB
Executive Vice President, Medical and Health Sciences
Dean of the Medical Faculty
Cedars-Sinai
Los Angeles, CA
Dr. Melmed has no relevant relationships to disclose.
Lisa Nachtigall, MD
Clinical Director, Neuroendocrine & Pituitary Tumor Clinical Center
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Nachtigall has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Rosa Rojas has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Apply up-to-date diagnostic guidelines to ensure rapid and accurate identification of acromegaly in clinical practice
- Evaluate current medical management options for acromegaly, including their real-world effectiveness, to optimize treatment outcomes.
- Analyze emerging medical management therapies, including oral options, to integrate innovative treatments into personalized care strategies for acromegaly.
Target Audience
This activity has been designed to meet the educational needs of endocrinologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with acromegaly.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hour(s)/0.15 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-063-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an independent educational grant from Crinetics Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Details
Presenters
Overview
Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnosis, averaging 4 to 6 years, which exacerbates disease progression and leads to irreversible comorbidities such as cardiovascular disease, diabetes mellitus, and sleep apnea. Join our live symposium for a deep dive into the diagnostic guidelines and the latest clinical insights and treatment strategies to enhance patient care. Don’t miss this opportunity to gain practical, expert-driven guidance on optimizing acromegaly management.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Maria Fleseriu, MD
Professor of Medicine (Endocrinology, Diabetes and Clinical Nutrition) and Neurological Surgery
Director Pituitary Center
Oregon Health & Sciences University
Portland, OR
Dr. Fleseriu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Amolyt, Camurus, Crinetics Pharmaceuticals, Debiopharm, Recordati
Research: Crinetics Pharmaceuticals
Faculty:
Shlomo Melmed, MBChB
Executive Vice President, Medical and Health Sciences
Dean of the Medical Faculty
Cedars-Sinai
Los Angeles, CA
Dr. Melmed has no relevant relationships to disclose.
Lisa Nachtigall, MD
Clinical Director, Neuroendocrine & Pituitary Tumor Clinical Center
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Nachtigall has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Rosa Rojas has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Rosanne Strauss, PharmD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Apply up-to-date diagnostic guidelines to ensure rapid and accurate identification of acromegaly in clinical practice
- Evaluate current medical management options for acromegaly, including their real-world effectiveness, to optimize treatment outcomes.
- Analyze emerging medical management therapies, including oral options, to integrate innovative treatments into personalized care strategies for acromegaly.
Target Audience
This activity has been designed to meet the educational needs of endocrinologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with acromegaly.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.5 contact hour(s)/0.15 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-063-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an independent educational grant from Crinetics Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Recommended
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
0.25 credits
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
CME/CERevolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
0.50 creditsMarilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
0.50 creditsVera Bril, MD
Nicholas J. Silvestri, MD
Hans Katzberg, MD
1.00 credit 10 episodesPreventing Myasthenic Crisis: Early Signs and Critical Interventions
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
MinuteCE®Preventing Myasthenic Crisis: Early Signs and Critical Interventions
1.00 program creditVera Bril, MD
Hans Katzberg, MD
1.00 program credit